![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LSM1 |
Gene summary for LSM1 |
![]() |
Gene information | Species | Human | Gene symbol | LSM1 | Gene ID | 27257 |
Gene name | LSM1 homolog, mRNA degradation associated | |
Gene Alias | CASM | |
Cytomap | 8p11.23 | |
Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | A0A0S2Z590 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27257 | LSM1 | GSM4909291 | Human | Breast | IDC | 6.32e-03 | 3.49e-01 | 0.1753 |
27257 | LSM1 | GSM4909296 | Human | Breast | IDC | 4.64e-04 | -6.91e-02 | 0.1524 |
27257 | LSM1 | GSM4909297 | Human | Breast | IDC | 6.30e-17 | 5.33e-01 | 0.1517 |
27257 | LSM1 | GSM4909308 | Human | Breast | IDC | 6.73e-04 | 3.05e-01 | 0.158 |
27257 | LSM1 | GSM4909309 | Human | Breast | IDC | 8.63e-13 | 5.17e-01 | 0.0483 |
27257 | LSM1 | GSM4909311 | Human | Breast | IDC | 7.79e-14 | -1.80e-01 | 0.1534 |
27257 | LSM1 | GSM4909312 | Human | Breast | IDC | 3.51e-06 | -1.30e-01 | 0.1552 |
27257 | LSM1 | GSM4909313 | Human | Breast | IDC | 1.46e-03 | -1.44e-01 | 0.0391 |
27257 | LSM1 | GSM4909317 | Human | Breast | IDC | 3.39e-16 | 5.37e-01 | 0.1355 |
27257 | LSM1 | GSM4909318 | Human | Breast | IDC | 6.17e-20 | 1.08e+00 | 0.2031 |
27257 | LSM1 | GSM4909319 | Human | Breast | IDC | 2.50e-19 | -6.03e-02 | 0.1563 |
27257 | LSM1 | GSM4909321 | Human | Breast | IDC | 6.95e-07 | -7.68e-02 | 0.1559 |
27257 | LSM1 | brca1 | Human | Breast | Precancer | 1.82e-03 | 3.27e-01 | -0.0338 |
27257 | LSM1 | NCCBC14 | Human | Breast | DCIS | 1.15e-02 | 6.47e-02 | 0.2021 |
27257 | LSM1 | NCCBC2 | Human | Breast | DCIS | 1.12e-06 | 4.76e-01 | 0.1554 |
27257 | LSM1 | NCCBC5 | Human | Breast | DCIS | 1.12e-04 | 1.01e-03 | 0.2046 |
27257 | LSM1 | P1 | Human | Breast | IDC | 1.80e-08 | -2.00e-01 | 0.1527 |
27257 | LSM1 | P2 | Human | Breast | IDC | 1.25e-26 | 8.66e-01 | 0.21 |
27257 | LSM1 | DCIS2 | Human | Breast | DCIS | 2.87e-35 | 8.78e-02 | 0.0085 |
27257 | LSM1 | LZE2T | Human | Esophagus | ESCC | 1.28e-03 | 8.37e-01 | 0.082 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
GO:00311242 | Oral cavity | OSCC | mRNA 3'-end processing | 49/7305 | 62/18723 | 1.40e-10 | 4.14e-09 | 49 |
GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:006101316 | Oral cavity | OSCC | regulation of mRNA catabolic process | 105/7305 | 166/18723 | 2.04e-10 | 5.82e-09 | 105 |
GO:00343405 | Oral cavity | OSCC | response to type I interferon | 46/7305 | 58/18723 | 4.17e-10 | 1.11e-08 | 46 |
GO:00603374 | Oral cavity | OSCC | type I interferon signaling pathway | 41/7305 | 50/18723 | 5.59e-10 | 1.46e-08 | 41 |
GO:004348716 | Oral cavity | OSCC | regulation of RNA stability | 106/7305 | 170/18723 | 5.65e-10 | 1.47e-08 | 106 |
GO:00713574 | Oral cavity | OSCC | cellular response to type I interferon | 42/7305 | 52/18723 | 8.50e-10 | 2.13e-08 | 42 |
GO:004348816 | Oral cavity | OSCC | regulation of mRNA stability | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
GO:19019875 | Oral cavity | OSCC | regulation of cell cycle phase transition | 209/7305 | 390/18723 | 2.79e-09 | 6.42e-08 | 209 |
GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
GO:00459319 | Oral cavity | OSCC | positive regulation of mitotic cell cycle | 77/7305 | 121/18723 | 3.49e-08 | 6.64e-07 | 77 |
GO:00610149 | Oral cavity | OSCC | positive regulation of mRNA catabolic process | 58/7305 | 87/18723 | 1.59e-07 | 2.61e-06 | 58 |
GO:00903076 | Oral cavity | OSCC | mitotic spindle assembly | 46/7305 | 65/18723 | 2.06e-07 | 3.29e-06 | 46 |
GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
GO:00000826 | Oral cavity | OSCC | G1/S transition of mitotic cell cycle | 120/7305 | 214/18723 | 2.86e-07 | 4.40e-06 | 120 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030186 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301811 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301821 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa0301831 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa030184 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa030185 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa0301810 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
hsa0301815 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LSM1 | SNV | Missense_Mutation | novel | c.98N>A | p.Arg33Lys | p.R33K | O15116 | protein_coding | deleterious(0.04) | possibly_damaging(0.71) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LSM1 | SNV | Missense_Mutation | c.146N>A | p.Arg49His | p.R49H | O15116 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
LSM1 | SNV | Missense_Mutation | c.364N>A | p.Leu122Ile | p.L122I | O15116 | protein_coding | tolerated(0.05) | benign(0.209) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LSM1 | SNV | Missense_Mutation | c.176T>G | p.Ile59Ser | p.I59S | O15116 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
LSM1 | deletion | Frame_Shift_Del | c.165delA | p.Lys55AsnfsTer20 | p.K55Nfs*20 | O15116 | protein_coding | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |||
LSM1 | SNV | Missense_Mutation | novel | c.238G>A | p.Glu80Lys | p.E80K | O15116 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LSM1 | SNV | Missense_Mutation | novel | c.312N>T | p.Gln104His | p.Q104H | O15116 | protein_coding | deleterious(0.02) | benign(0.428) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
LSM1 | SNV | Missense_Mutation | novel | c.382N>A | p.Asp128Asn | p.D128N | O15116 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
LSM1 | SNV | Missense_Mutation | novel | c.145C>T | p.Arg49Cys | p.R49C | O15116 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
LSM1 | SNV | Missense_Mutation | c.263N>G | p.Gln88Arg | p.Q88R | O15116 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |